Holen Sie sich die Stockscreener-App
187.62
0.87%
1.62
Handel nachbörslich:
187.60
-0.02
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Here's What Analysts Think About Biogen Inc. (BIIB) - Finviz
Here’s What Analysts Think About Biogen Inc. (BIIB) - Insider Monkey
EBIT per share of Biogen Inc. – DUS:IDP - TradingView — Track All Markets
Biogen Advances New SKYCLARYS Formulation in Early Trial, Supporting Long-Term Rare Disease Strategy - TipRanks
Bernstein Adjusts Price Target on Biogen to $197 From $157, Maintains Market Perform Rating - MarketScreener
Biogen’s Alzheimer’s Treatment Gains Crucial Momentum in Chinese Market - AD HOC NEWS
Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - simplywall.st
Responsive Playbooks and the BIIB Inflection - Stock Traders Daily
How Biogen Inc. stock performs in high volatility marketsJobs Report & Weekly Watchlist of Top Performers - ulpravda.ru
Will Biogen Inc. stock continue dividend increasesJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
How Biogen Inc. stock compares to growth peersEarnings Growth Summary & Verified Entry Point Detection - ulpravda.ru
Will Biogen Inc. stock split again soonJuly 2025 EndofMonth & Fast Momentum Stock Entry Tips - ulpravda.ru
What catalysts could drive Biogen Inc. stock higherJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - ulpravda.ru
Truist Securities Raises Price Target for Biogen (BIIB) Amid Hol - GuruFocus
RBC Raises Price Target on Biogen to $220 From $210, Keeps Outperform Rating - MarketScreener
Mizuho raises Biogen stock price target to $207 on improved 2026 catalyst outlook - Investing.com Canada
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen : to Report Fourth Quarter and Full Year 2025 Financial Results February 6, 2026 - MarketScreener
Biogen to Report Fourth Quarter and Full Year 2025 Financial Results February 6, 2026 - Biogen
Citigroup Raises Price Target for Biogen (BIIB) to $180, Keeps N - GuruFocus
UBS Adjusts Price Target on Biogen to $185 From $130, Maintains Neutral Rating - MarketScreener
Biogen stock hits 52-week high at 185.59 USD By Investing.com - Investing.com South Africa
Biogen stock hits 52-week high at 185.59 USD - Investing.com
UBS Adjusts Price Target for Biogen (BIIB) with Neutral Rating | - GuruFocus
Analyst Expectations For Biogen's Future - Benzinga
What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders - Yahoo Finance
Spinal Muscular Atrophy Market Insights 2026-2033: Global - openPR.com
Biogen stock rating maintained at Neutral by UBS, price target raised - Investing.com Canada
Biogen Inc.: Can a Neuroscience Pioneer Still Out-Innovate a Ruthless Market? - AD HOC NEWS
Biogen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Biogen
Biogen Stock at a Crossroads: Alzheimer Hopes, Biotech Volatility and a Market Running Out of Patien - AD HOC NEWS
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment - Benzinga
Did China’s At‑Home LEQEMBI Review Just Shift Biogen's (BIIB) Alzheimer’s Care Investment Narrative? - simplywall.st
Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application - Yahoo Finance
Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi for Treatment of Early Alzheimer's Disease - MarketScreener
Biogen (BIIB) Receives a Hold from Bank of America Securities - The Globe and Mail
Will Biogen Inc. stock benefit from sector rotationSwing Trading Ideas & Small Investment Trading Plans - bollywoodhelpline.com
Biogen’s Stock Awaits Key Regulatory Catalyst in China - AD HOC NEWS
BIIB: Biogen's LEQEMBI Application Accepted in China - GuruFocus
Eisai and Biogen Announce Acceptance of Biologics License Application for Subcutaneous LEQEMBI® in China - Quiver Quantitative
Biogen : Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China - MarketScreener
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China - Biogen
Biologics License Application for Subcutaneous Formulation - GlobeNewswire
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe - BioSpace
Inside Biotech: A potential paradigm shift in Alzheimer’s therapy — reversal, not just slowing - Proactive financial news
Biogen Inc. (BIIB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biosimilars Market is expected to reach US$ 171.79 billion - openPR.com
Biogen Inc. $BIIB Stock Position Increased by Cwm LLC - MarketBeat
Biotech pioneer who helped launch Biogen dies at 94 - The Business Journals
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge (NASDAQ:BIIB) - Seeking Alpha
Dementia Drugs Market 2025 Outlook: In-Depth Insights, - openPR.com
Ethic Inc. Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Spinal Muscular Atrophy Market is expected to reach US$ 20.06 - openPR.com
Recombinant Therapeutic Antibodies And Proteins Market - openPR.com
J. L. Bainbridge & Co. Inc. Cuts Holdings in Biogen Inc. $BIIB - MarketBeat
Vontobel Holding Ltd. Sells 18,760 Shares of Biogen Inc. $BIIB - MarketBeat
Pacer Advisors Inc. Acquires 131,258 Shares of Biogen Inc. $BIIB - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Swedbank AB Grows Stake in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc Gaining or Losing Market Support?Biogen (NASDAQ:BIIB) - Benzinga
1.87%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):